Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide.

Autor: Hu, Shanshan1 (AUTHOR), Shi, Chenyang1 (AUTHOR), Ma, Yuhang2 (AUTHOR), Wang, Shuowen1 (AUTHOR), Gu, Shengying1 (AUTHOR), Qi, Chendong1 (AUTHOR) poohqi25@163.com, Fan, Guorong1 (AUTHOR) guorfan@163.com
Zdroj: Diabetes, Obesity & Metabolism. Aug2024, Vol. 26 Issue 8, p3176-3190. 15p.
Databáze: Academic Search Ultimate
Externí odkaz: